pharmacotherapy for anxiety in children & adolescents · pdf filepharmacotherapy for...
TRANSCRIPT
![Page 1: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/1.jpg)
Pharmacotherapy for
Anxiety in Children &
Adolescents
Daniel S. Pine, MD
![Page 2: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/2.jpg)
Disclosures: Conflicts
Sources of Research Support
National Institute of Mental Health
Paid Editorial Relationship Am J Psychiatry– Deputy Editor
Consulting RelationshipsNone
Stock Equity (>$10,000)None
Speaker’s BureauNone
Role in pharmacology, DSM-5
FDA Committee & Black Box Vote
“Off-Label” use
My perspective
![Page 3: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/3.jpg)
Outline & Objectives
Classifying Pediatric Mood & Anxiety
Broad categorization schemes
Outcome & treatment implications
Current Treatments
Finding Novel Treatments
Underlying neurobiology
Using neuroscience to guide discovery?
![Page 4: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/4.jpg)
Outline & Objectives
Classifying Pediatric Mood & Anxiety
Broad categorization schemes
Outcome & treatment implications
![Page 5: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/5.jpg)
Long history of debate
Harmful dysfunction
Similar or different from other illness?
Defining Mental Illness
• Complexity of the brain
• Context specificity of signs & symptoms
• Identify extremes of “normal” behavior
• Signs, symptoms, & impairment
• Impact on function
![Page 6: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/6.jpg)
19801987
19942000
2013
DSM-III
The Diagnostic and Statistical Manual
![Page 7: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/7.jpg)
DSM-5 Classification & Anxiety
Mostly minor change, except for structure revision process
placement of child disorders
broad disorder groupings
move toward dimensions
Changes in anxiety minor (e.g., vs. Autism)
![Page 8: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/8.jpg)
OCD
Associations with tics, ADHD
Basal ganglia dysfunction, PANDAS Leckman, Leonard, Peterson, Rosenberg, Swedo, others
PTSD
Longitudinal associations with wide array of disorders
HPA axis dysfunctionDeBellis, Heim, Nemeroff, Pynoos, others
Social Anxiety, GAD, Separation Anxiety, [Phobias]
Considered as a group in most major treatment studiesBiederman, Kendal, Kessler, Pine, Rosenbaum, Weissman, others
Specific Association with MDD and “distress vs. fear”?Particularly GAD?
DSM-5 & Anxiety
![Page 9: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/9.jpg)
DSM-5 Classification & Mood Disorders
Mostly minor, except bipolar disorder
Controversy about bipolar disorder
Classic presentation is rare
How to classify chronically irritable child?
Disruptive Mood Dysregulation Disorder
![Page 10: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/10.jpg)
RDoC: What is RDoC???
Based in neuroscience
Focuses on Narrow Behaviors
Focuses on Dimensions
![Page 11: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/11.jpg)
Avoidance
What is avoidance & where do we see?
Predicts many bad things
How does environment respond?
Cut the sutures too short or long?
![Page 12: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/12.jpg)
Longitudinal Data
Clinic-based
Family-based
Community-based
Sub-clinical Precursors
![Page 13: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/13.jpg)
Any Adolescent Anxiety Disorder & Any
Adult Mood/Anxiety Disorder
Disorder as Adults?
Disorder as
Adolescents?
No Yes
No 390 36 426
Yes 191 62 253
581 98 679
Pine et al. 1998, 2001, 2002
![Page 14: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/14.jpg)
Any Adolescent Anxiety Disorder & Any
Adult Mood/Anxiety Disorder
Disorder as Adults?
Disorder as
Adolescents?
No Yes
No 390 36 426
Yes 191 62 253
581 98 679
Pine et al. 1998, 2001, 2002
![Page 15: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/15.jpg)
Any Adolescent Anxiety Disorder & Any
Adult Mood/Anxiety Disorder
Disorder as Adults?
Disorder as
Adolescents?
No Yes
No 390 36 426
Yes 191 62 253
581 98 679
Pine et al. 1998, 2001, 2002
![Page 16: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/16.jpg)
Any Adolescent Anxiety Disorder & Any
Adult Mood/Anxiety Disorder
Disorder as Adults?
Disorder as
Adolescents?
No Yes
No 390 36 426
Yes 191 62 253
581 98 679
Pine et al. 1998, 2001, 2002
![Page 17: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/17.jpg)
Outline & Objectives
Classifying Pediatric Mood & Anxiety
Broad categorization schemes
Outcome & treatment implications
![Page 18: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/18.jpg)
Outline & Objectives
Classifying Pediatric Mood & Anxiety
Broad categorization schemes
Outcome & treatment implications
Current Treatments
![Page 19: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/19.jpg)
Major Depression
SSRI Medications
Psychotherapy: CBT? & IPT?
Anxiety Disorders
SSRI Medications
Psychotherapy: CBT
Treatment
![Page 20: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/20.jpg)
SSRIs, CBT, & Efficacy
in Pediatric Anxiety
![Page 21: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/21.jpg)
SSRIs, CBT & Pediatric Anxiety: Efficacy
SSRI evidence for efficacy in GAD, social anxiety, separation anxiety disorder
Particularly good evidence for fluvoxamine, fluoxetine, paroxetine, sertraline, (duloxetine, venlafaxine)
Also good evidence for CBT
Comparative efficacy of SSRIs & CBT?
![Page 22: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/22.jpg)
![Page 23: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/23.jpg)
Rates of Improvement
Study Difference PBO SSRI
RUPP Anxiety Study (2001) 47% 29% 76%
Birmaher et al. (2003) 25% 36% 61%
Rynn et al. (2001) 80% 10% 90%
Wagner et al. (2004) 40% 38% 78%
Walkup et al. (2008) 31% 24% 55%
Rynn et al. (2007) 12% 24% 36%
Total 30% 31% 61%
Meta-Analysis: Rates of Improvement
NNT=3.3
![Page 24: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/24.jpg)
Cognitive Behavioral Therapy
Evidence of Efficacy
Quite strong
Specificity in therapy procedures
How does CBT work?
Make “fear hierarchy”
Learn new techniques
Graded exposure
Importance of patient’s control and success
Role of the therapist?
![Page 25: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/25.jpg)
![Page 26: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/26.jpg)
2015
2015
2014
![Page 27: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/27.jpg)
SSRIs, CBT, & Efficacy in Pediatric
Major Depressive Disorder (MDD)
![Page 28: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/28.jpg)
SSRIs and Pediatric MDD: Efficacy
fluoxetine works (3 of 3½ studies)
Weak evidence for sertraline (not really), citalopram (2 of 4 studies)
FDA Approval: fluoxetine/prozac; escitalopram/lexapro
Some (very weak) evidence for paroxetine
Virtually no evidence for other agents
What gives?
Data in adults that strong?
Differences among the SSRIs?
Differences in placebo response, sample, assessment
![Page 29: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/29.jpg)
• Results– Fluoxetine vs. placebo
– CBT vs. placebo
• What does this mean?– Strong role of expectancy
– What do we recommend to patients?
• First Line Treatments?
![Page 30: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/30.jpg)
• Bottom Line?– Only significant benefit was for CBT
![Page 31: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/31.jpg)
SSRIs and Controversy
![Page 32: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/32.jpg)
SSRIs and Controversy
Biased reporting of data for efficacy
![Page 33: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/33.jpg)
Biased Reporting in Adult Antidepressant TrialsTurner et al. NEJM 2008
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
Effect Size (Hedge's g)
All Data
Published Data
Only
Unpublished
Data Only
Bias in Publication Bias in Magnitude of Clinical Effect
![Page 34: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/34.jpg)
SSRIs and Controversy
Concerns about suicidal ideation
![Page 35: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/35.jpg)
FDA Analysis from December, 2006
Antidepressants and Thoughts About Suicide
![Page 36: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/36.jpg)
SSRIs and Controversy
FDA & Black Box
![Page 37: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/37.jpg)
Bottom Line of the SSRIs
SSRIs are very effective in the treatment of
pediatric anxiety (and OCD).
Of the SSRIs, only fluoxetine and citalopram
have been shown to be effective in pediatric
MDD, and the NNT is large.
Increased risk of suicidality with SSRIs is
real, but the magnitude of the effect is small.
![Page 38: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/38.jpg)
Pediatric Bipolar Disorder
![Page 39: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/39.jpg)
DSM-5 Classification & Mood Disorders
Mostly minor, except bipolar disorder
Controversy about bipolar disorder
Classic presentation is rare
How to classify chronically irritable child?
Disruptive Mood Dysregulation Disorder
![Page 40: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/40.jpg)
Treatment of Bipolar Disorder Wide use of many medications
FDA: aripipazole (Abilify)
quetiapine (Seroquel)
risperidone (Risperdol)
olanzapine (Zyprexa) (ages 13 to 17)
No evidence for anticonvulsants
FDA Approval for lithium (13 to 17)
Not much other strong data; concerns about safety
(age 10 to 17)
![Page 41: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/41.jpg)
![Page 42: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/42.jpg)
Practical Points
Anxiety easier to treat than mood
Two good treatments available
Importance of exposure in anxiety
Mood disorders are very serious; handle with care and experts
![Page 43: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/43.jpg)
Outline & Objectives
Classifying Pediatric Mood & Anxiety
Broad categorization schemes
Outcome & treatment implications
Current Treatments
Finding Novel Treatments
Underlying neurobiology
Using neuroscience to guide discovery?
![Page 44: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/44.jpg)
SEROTONIN ANATOMY
![Page 45: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/45.jpg)
SEROTONIN ANATOMY
![Page 46: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/46.jpg)
Development,
Anxiety, & 5-HT1a R
Gross et al. Nature 2002
5-HT1a receptor must be present
pre-adolescence to “rescue” anxious
phenotype.
The effect of SSRIs on developing
nervous system is not fully understood
Ansorge et al (2004)
Science
![Page 47: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/47.jpg)
![Page 48: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/48.jpg)
VISUAL
CORTEX
AMYGDALA
HEART RATE
BLOOD PRESSURE MUSCLE
VISUAL THALAMUS
LeDoux. Sci Am. 1994;270:50.
![Page 49: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/49.jpg)
Attention Retraining Therapy
Schmidt et al. 2008
Training of Attention
Changes in SPAI in n=36 patients with Social Phobia
![Page 50: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/50.jpg)
Meta-Analysis: Training Studies
Hakamata et al. 2010
![Page 51: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/51.jpg)
Randomized Controlled Trial
0
2
4
6
8
10
12
Train to Neutral Train to AngryA
nxie
ty S
co
re
Eldara, Ricona, & Bar-Haim 2008Training of Attention
Altered Response to Stress
n=15 n=15 n=10
Four-Week Treatment Outcomes in Pediatric Anxiety Disorders
Eldar et al. 2012
![Page 52: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/52.jpg)
![Page 53: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/53.jpg)
![Page 54: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/54.jpg)
Any Adolescent Anxiety Disorder & Any
Adult Mood/Anxiety Disorder
Disorder as Adults?
Disorder as
Adolescents?
No Yes
No 390 36 426
Yes 191 62 253
581 98 679
Pine et al. 1998, 2001, 2002
![Page 55: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/55.jpg)
Ressler & Davis 2003
Ressler & Davis 2003
![Page 56: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/56.jpg)
Ressler & Davis 2003
Extinction:
Not forgetting but new learning
Anxiety disorders as problems in new learning
Ressler & Davis 2003
![Page 57: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/57.jpg)
Ressler & Davis 2003
NMDA manipulation
Ressler & Davis 2003NMDA manipulations?
![Page 58: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/58.jpg)
Copyright restrictions may apply.
Ressler, K. J. et al. Arch Gen Psychiatry 2004;61:1136-1144.
Acrophobia within the virtual environment is improved with D-cycloserine
Positive findings in some…Guastella et al. 2008; Hofmann et al. 2006; Wilhelm et al. 2008;
but not in other…studies.Guastella et al. 2007; Kushner et al. 2007; Rothbaum et al. 2014; Storch et al. 2007, 2010
Data on Social Phobia are equivocal
Hoffman et al. Am J Psychiatry 2013;170:751-358.
Panic Disorder is improved with D-cycloserine
Otto et al. Biol Psychiatry 2010
![Page 59: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/59.jpg)
Practical Points
We know much about anxiety
Basic knowledge informs treatment
Informs treatments we have
May lead to new treatments
![Page 60: Pharmacotherapy for Anxiety in Children & Adolescents · PDF filePharmacotherapy for Anxiety in Children & Adolescents Daniel S. Pine, MD. Disclosures: Conflicts Sources of Research](https://reader030.vdocument.in/reader030/viewer/2022020315/5aa369ac7f8b9a436d8e2215/html5/thumbnails/60.jpg)
Outline & Objectives
Classifying Pediatric Mood & Anxiety
Broad categorization schemes
Outcome & treatment implications
Current Treatments
Finding Novel Treatments
Underlying neurobiology
Using neuroscience to guide discovery?